Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir.

Ditte Marie Kirkegaard-Klitbo, Magda Teresa Thomsen, Marco Gelpi, Flemming Bendtsen, Susanne Dam Nielsen, Thomas Benfield

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021;73(3):e811-e814

PMID: 33493297

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.

Address: CREDID, Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark.; Viro-immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Gastrounit, Medical Division, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark.; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

DOI: 10.1093/cid/ciab057

Link outs

Free resources

Medical:

Other Literature Sources:

https://scite.ai/reports/33493297

Subscription / membership required

Full Text Sources:

MeSH Terms: HIV Infections, Humans, Prospective Studies, Quinolones, Raltegravir Potassium